FDA clears Prime Medicine's IND for AATD gene editing therapy
Prime Medicine, Inc. (Nasdaq: PRME) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

